• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Vicore Pharma Holding

11.50 SEK

+3.60 %

Less than 1K followers

VICO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+3.60 %
+0.17 %
+13.86 %
+1.77 %
+17.11 %
+44.11 %
-32.69 %
-47.59 %
+127.72 %

Vicore Pharma Holding operates in the pharmaceutical industry and focuses on the development of innovative treatments for pulmonary and cardiovascular diseases. The company researches new therapies that can improve patient outcomes and quality of life. The business is global with a primary presence in Europe and North America. Vicore Pharma was founded in 2000 and is headquartered in Gothenburg, Sweden.

Read more
Market cap
3.24B SEK
Turnover
13.79M SEK
Revenue
3.82M
EBIT %
-11,851.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

Press release6/2/2026, 6:00 AM

Vicore Pharma arrangerar webcast om buloxibutid och det framväxande landskapet för IPF-behandlingar

Vicore Pharma Holding
Press release6/2/2026, 6:00 AM

Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape

Vicore Pharma Holding
Press release5/26/2026, 6:00 AM

Vicore Pharma presenterar på Jefferies Global Healthcare Conference

Vicore Pharma Holding

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/26/2026, 6:00 AM

Vicore Pharma to Present at the Jefferies Global Healthcare Conference

Vicore Pharma Holding
Press release5/22/2026, 12:38 PM

Vicore Pharma går vidare med amerikansk sekundärnotering och lämnar in registreringshandling till SEC

Vicore Pharma Holding
Press release5/22/2026, 12:38 PM

Vicore Pharma Pursues US Dual Listing, Files Registration Statement with the SEC

Vicore Pharma Holding
Regulatory press release5/11/2026, 7:07 AM

Finansinspektionen: Flaggningsmeddelande i Vicore Pharma Holding AB

Vicore Pharma Holding
Press release5/7/2026, 11:51 AM

Investor Studios: Vicore Pharmas VD & CMO intervjuas om IPF, buloxibutid & ASPIRE-studien

Vicore Pharma Holding
Press release5/7/2026, 6:00 AM

Vicore Pharma utser Peter Guenter till styrelseledamot

Vicore Pharma Holding
Press release5/7/2026, 6:00 AM

Vicore Pharma Elects Peter Guenter to its Board of Directors

Vicore Pharma Holding
Regulatory press release5/6/2026, 2:30 PM

Kommuniké från årsstämma i Vicore Pharma Holding AB (publ)

Vicore Pharma Holding
Regulatory press release5/6/2026, 2:30 PM

Announcement from the Annual General Meeting of Vicore Pharma Holding AB (publ)

Vicore Pharma Holding
Regulatory press release5/6/2026, 6:00 AM

Delårsrapport januari – mars 2026

Vicore Pharma Holding
Regulatory press release5/6/2026, 6:00 AM

Interim Report January – March 2026

Vicore Pharma Holding
Press release4/29/2026, 6:00 AM

Vicore Pharma medverkar med posterpresentationer vid ATS International Conference 2026

Vicore Pharma Holding
Press release4/29/2026, 6:00 AM

Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference

Vicore Pharma Holding
Press release4/22/2026, 6:00 AM

Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis

Vicore Pharma Holding
Press release4/22/2026, 6:00 AM

Vicore Pharma slutför rekryteringen i fas 2b-studien ASPIRE med buloxibutid i idiopatisk lungfibros

Vicore Pharma Holding
Regulatory press release4/1/2026, 7:00 AM

KALLELSE TILL ÅRSSTÄMMA I VICORE PHARMA HOLDING AB (PUBL)

Vicore Pharma Holding
Regulatory press release4/1/2026, 7:00 AM

NOTICE OF ANNUAL GENERAL MEETING IN VICORE PHARMA HOLDING AB (PUBL)

Vicore Pharma Holding